JAN 13, 2022 7:30 AM PST

Convalescent Plasma Therapy 'Keeps up' With COVID Variants

WRITTEN BY: Tara Fernandes

A recent study has demonstrated that COVID-19 convalescent plasma treatment (or blood from individuals who have recovered from the disease) can slash the risk of hospitalization by over 50 percent. These plasma therapies are rich in antibodies against SARS-CoV-2, produced by the immune systems of patients who have successfully fought off the virus.

As the pandemic rages on worldwide, low- and middle-income countries are in desperate need of accessible frontline COVID-19 therapies to save lives. In these settings, vaccines, monoclonal antibodies, and other COVID therapeutics may not be readily available, which forced researchers from the Johns Hopkins University School of Medicine to seek out potential alternatives.

David Sullivan led a study involving over 1000 randomized adult COVID-19 patients who received one of two transfusion treatments for their infection: convalescent plasma or a control plasma (without SARS-CoV-2 antibodies). All the patients in the study had tested positive for COVID in the week leading up to receiving the transfusion. 

Sullivan and colleagues defined treatment success as a patient who did not require hospitalization for their symptoms within around a month of receiving the transfusion. The researchers reported that 2.9 percent of those who received convalescent plasma needed to be admitted into the hospital. Conversely, 6.3 percent of those in the placebo group were hospitalized, which translates to a risk reduction of 54 percent with the convalescent plasma.

Sullivan says that this represents a viable option to help reduce hospitalizations, adding that convalescent plasma therapy is the only one that “keeps up with SARS-CoV-2 variants,” including the Delta and Omicron strains currently circulating globally because the plasma contains neutralizing antibodies specific to those variants.

In the United States, convalescent plasma therapy has been given an emergency use authorization designation by the Food and Drug Administration, limiting its use for COVID-19 outpatients.

“We have shared our findings with the FDA, as well as with the World Health Organization,” said Sullivan. “We hope that both organizations will see the value of convalescent plasma for outpatients based on the strength of our study, the largest randomized clinical trial of its kind to date.”

Despite the success of this trial, data from previous studies showed that convalescent therapy did not improve outcomes for patients at the early stages of COVID-19 infection. In this prior study, the authors attributed the failure of plasma therapy to several factors, including insufficient plasma doses, the timing of plasma administration, host-related factors, or other aspects of the host tissue responses to the infection.

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
FEB 25, 2022
Cancer
Does Exercise Help Prep Tumors for Surgery?
FEB 25, 2022
Does Exercise Help Prep Tumors for Surgery?
Esophageal cancer, also known as cancer of the food pipe, gullet cancer, or oesophageal cancer, develops in the tube tha ...
MAR 11, 2022
Clinical & Molecular DX
A Cost-Effective Universal Screening Program for Type 1 Diabetes
MAR 11, 2022
A Cost-Effective Universal Screening Program for Type 1 Diabetes
Type 1 diabetes (T1D) describes a disorder that presents when the pancreas cannot produce insulin, a hormone needed to r ...
MAR 10, 2022
Health & Medicine
New Study States Natural Immunity to COVID Lasted up to 15 months in the Majority of Its Cohorts
MAR 10, 2022
New Study States Natural Immunity to COVID Lasted up to 15 months in the Majority of Its Cohorts
From the beginning of the pandemic to late January 2022 during the Omicron wave, the CDC estimates that 43% of the US po ...
MAR 14, 2022
Immunology
Many Variants of the Virus Can Hide Away in COVID-19 Patients
MAR 14, 2022
Many Variants of the Virus Can Hide Away in COVID-19 Patients
Though it may happen at different rates for different microbes, mutations happen, and SARS-CoV-2, the virus that causes ...
MAR 17, 2022
Immunology
How Bacteria Can Keep Intestinal Inflammation in Check
MAR 17, 2022
How Bacteria Can Keep Intestinal Inflammation in Check
We need bile acids to help us digest food and absorb nutrients. New research has shown how bile acids modified by bacter ...
MAY 06, 2022
Immunology
Epstein-Barr Virus Vaccine Enters Phase 1 Trials
MAY 06, 2022
Epstein-Barr Virus Vaccine Enters Phase 1 Trials
The Epstein-Barr virus (EBV) infects most people; it's thought that when we're young, about 90 percent of us acq ...
Loading Comments...